The evolution of ECMO from a last-resort intervention to a mainstay of modern critical care is a testament to the relentless pursuit of better patient outcomes in the field of medicine. Unfortunately, despite the immense life-saving capability of this therapy, it remains vastly underutilized.
Alviss.ai CEO and Founder Dr. Pavel Overtchouk talks about how the company’s stroke prediction software seeks to be the first attempt to apply predictive medicine to cardiovascular interventions and heart surgery.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Join us tomorrow for a webinar sponsored by Medable as we explore challenges of drug innovation in the cardiometabolic space and how connected devices could make evidence collection less costly and more efficient to support regulatory evaluation and approvals.
Bristol Myers Squibb drug Camzyos has FDA approval for treating obstructive hypertrophic cardiomyopathy, a rare and potentially fatal heart disorder. The drug is projected to become a blockbuster seller and its approval marks a payoff for BMS’s 2020 acquisition of the medicine’s developer, MyoKardia.
The cancer and cardiovascular care provider has teamed up with GE Healthcare, granting its 440 centers in the U.S., U.K., Spain and Australia access to GE equipment and services. The organizations will also explore research opportunities.
The deal will make the Phase III drug inclisiran - which Novartis acquired when it bought The Medicines Company in November - available to patients in the U.K. and include manufacturing and clinical development efforts.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Fitting corrective medical devices to a growing child is highly complex — particularly when they’ve got congenital cardiovascular conditions. Boston startup 480 Biomedical is developing a self-expanding scaffold that can be resorbed by the body to treat such disorders in children. The company just received $1 million in Phase II funding from the National Heart, Lung and Blood Institute to continue […]
A changing of the guard: Dan Brennan will become Boston Scientific‘s (BSX) new CFO effective Jan. 1. Company CFO Jeffrey Capello will stay with the company through May to help as a senior advisor and probably to help Brennan transition into the role. His reason for leaving is still vague. A company statement said he […]